Cardiva Medical Revenue and Competitors

Claim your profile

Location

$181.2M

Total Funding

Estimated Revenue & Valuation

  • Cardiva Medical's estimated annual revenue is currently $53M per year.(i)
  • Cardiva Medical received $11.0M in venture funding in February 2018.
  • Cardiva Medical's estimated revenue per employee is $251,000
  • Cardiva Medical's total funding is $181.2M.

Employee Data

  • Cardiva Medical has 211 Employees.(i)
  • Cardiva Medical grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.8M79N/AN/AN/A
#2
$3.3M13N/AN/AN/A
#3
$6.5M26N/AN/AN/A
#4
$51.5M205-10%N/AN/A
#5
$8M32N/AN/AN/A
#6
$5M20N/AN/AN/A
#7
$23.1M920%$51.8MN/A
#8
$37.1M1480%N/AN/A
#9
$3.3M13N/AN/AN/A
#10
$1482.2M59056%N/AN/A

Cardiva Medical is a rapidly growing medical device company that designs and develops vascular access management products that facilitate rapid hemostasis following diagnostic and interventional cardiovascular procedures. Our latest advancement is the VASCADE® Vascular Closure System. VASCADE is SAFE. SIMPLE. GUARANTEED. In the Level 1 prospective, multi-center, randomized clinical trial called RESPECT (Hermiller et al), VASCADE was proven safer than manual compression and demonstrated ZERO(0) major complications. VASCADE is elegantly SIMPLE and provides both mechanical as well as physiologic hemostasis with ~13X expansion of collagen when hydrated, utilizing extravascular bioabsorbable collagen VASCADE is GUARANTEED. Because Cardiva Medical® is so committed and confident in VASCADE®'s ability to safely and rapidly achieve hemostasis, we offer a unique value-based purchasing program called the VASCADE® Performance Guarantee. In the event of a complication as the result of VASCADE, Cardiva Medical will provide significant financial reimbursement to your hospital or practice. It's simple, were dedicated to exceptional outcomes for you and your patients. We stand behind our product based upon published clinical studies and demonstrated superior performance in the surgical theater.

keywords:Healthcare,Human Resources Hr,Medical Devices,Medical Diagnostics,Pharmaceuticals

$181.2M

Total Funding

211

Number of Employees

$53M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cardiva Medical News

2022-04-17 - Arterial Incision Closure Device Market 2022: Covid-19 Impact ...

... Competitive Landscape, Growth Factors, Top Venders and Forecast Till 2028 : Abbott, Cardinal Health, Arstasis, Cardiva Medical.

2022-04-17 - Global Vascular Closure Systems Market 2022 Detail Analysis ...

Cardiva Medical; Endocor. Based on product type, the market is divided into types: Vascular Closure Devices; Sealant and Suture; Others. Based...

2022-04-17 - Vascular Closure Devices Market Size And Forecast | Abbott ...

... Closure Systems Vivasure Medical Ltd., Vasorum Ltd., Morris Innovative Inc., Cardiva Medical Terumo Corporation, Essential Medical, Inc.

2020-07-14 - Cardiva Medical Announces $45 Million Financing Led by EW Healthcare Partners

Jul 14 2020 Robert S. White Joins Board of Directors SANTA CLARA, California (GLOBE NEWSWIRE)—Cardiva Medical, Inc, an innovator in the field of vascular closure, today announced the completion of a $45 million equity financing round. The equity round included new investor EW Healthcare Partne ...

2020-07-14 - Cardiva Medical Announces $45 Million Financing Led by EW Healthcare Partners

SANTA CLARA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Cardiva Medical, Inc, an innovator in the field of vascular closure, today announced the completion of a $45 million equity financing round. The equity round included new investor EW Healthcare Partners in addition to Cardiva Medical’s exist ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.6M211N/AN/A
#2
$63.8M211-39%N/A
#3
$57.7M2162%N/A
#4
$65.9M2180%N/A
#5
$34.9M219N/AN/A

Cardiva Medical Funding

DateAmountRoundLead InvestorsReference
2005-06-24$8.3MBStockton Partners IncArticle
2006-05-24$14.0MCGalen PartnersArticle
2008-05-07$15.5MDPTV SciencesArticle
2014-08-13$12.5MUndisclosedGE CapitalArticle
2017-03-15$30.0MUndisclosedLuther King Capital ManagementArticle
2018-02-21$11.0MUndisclosedArticle